EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

The Role of Cardiovascular Risk Prediction Model Selection in Primary Prevention: An Observational Study of Statin Eligibility Agreement Across Nine Scores in a Lithuanian Primary-Prevention Cohort

Petras Navickas iD, Sigita Glaveckaitė iD, Laura Lukavičiūtė-Navickienė, Agnė Šatrauskienė iD, Arvydas Baranauskas iD, Egidija Rinkūnienė iD, Emilija Meškėnė, Vaida Šileikienė iD, Edita Lycholip, Aleksandras Laucevičius iD

Medicina · 17.05.2026 · 62 (5) · 979

DOI: 10.3390/medicina62050979 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Medicina, online erschienen am 17.05.2026. Verfasst von Petras Navickas und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiovascular Diseases, Primary Prevention. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Charity Fund Future Biomedicine Fund, Gediminas Gruodis donation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objectives: Cardiovascular risk prediction models (RPMs) are widely used to guide statin initiation in primary prevention, yet the extent to which different models produce concordant treatment decisions in the same population remains insufficiently characterized. We compared statin eligibility across nine commonly used RPMs: SCORE2, PREVENT, PCE, ASSIGN, FRS-hCHD, AusCVDRisk, MESA, QRISK3, and RRS. Materials and Methods: We performed a cross-sectional analysis of 11,174 adults aged 40–65 years with metabolic syndrome enrolled in the Lithuanian High Cardiovascular Risk primary prevention program (LitHiR) and evaluated them at a single tertiary center during 2006–2023. Statin eligibility was determined for each RPM using guideline-mapped treatment thresholds. Pairwise agreement was assessed using Cohen’s κ, Gwet’s AC1, Positive and Negative Percent Agreement (PPA/NPA), the Jaccard index, and McNemar testing. Analyses were repeated by sex. Consensus eligibility was defined as treatment recommended by at least k of nine models.

Results

Eligibility varied more than twenty-fold, from 67.39% (7530/11,174) with SCORE2 to 3.03% (339/11,174) with AusCVDRisk; intermediate estimates included PREVENT at 44.83%, QRISK3 at 39.00%, and PCE at 37.97%. Overall pairwise agreement was modest: κ ranged from 0.03 (SCORE2 vs. AusCVDRisk) to 0.67 (QRISK3 vs. ASSIGN), with a median κ of 0.38 (IQR: 0.19–0.51). Median AC1 was 0.58 (IQR 0.37–0.68). Agreement was stronger for non-eligibility than for eligibility (median NPA: 0.82 vs. median PPA: 0.53). Consensus eligibility declined from 73.5% at k = 1 to 45.1% at k = 3, 30.0% at k = 5, and 1.87% at k = 9, with the greatest sex divergence at intermediate stringency.

Conclusions

In this real-world cohort with elevated cardiometabolic risk, statin eligibility was highly dependent on RPM choice and showed only modest inter-model concordance. Increasing consensus stringency rapidly reduced eligibility, indicating that RPM selection and embedded thresholds substantially influence statin treatment decisions in primary prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiovascular DiseasesPrimary PreventionHumansLithuaniaMiddle AgedCross-Sectional StudiesMaleAdultFemaleRisk AssessmentAgedCohort StudiesHeart Disease Risk Factors

Stichwörter der Autor:innen

inter-model concordanceprimary cardiovascular preventionrisk prediction modelsstatin eligibility

Substanzen

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, LT-03101 Vilnius, Lithuania.
  • State Research Institute Centre for Innovative Medicine, LT-08406 Vilnius, Lithuania.

ORCID-Profile: Petras Navickas, Sigita Glaveckaitė, Agnė Šatrauskienė, Arvydas Baranauskas, Egidija Rinkūnienė, Vaida Šileikienė, Aleksandras Laucevičius

Förderung

  • Charity Fund Future Biomedicine Fund
  • Gediminas Gruodis donation

Zitieren

APA

Navickas, P., Glaveckaitė, S., Lukavičiūtė-Navickienė, L., Šatrauskienė, A., Baranauskas, A., Rinkūnienė, E., Meškėnė, E., Šileikienė, V., Lycholip, E., & Laucevičius, A. (2026). The Role of Cardiovascular Risk Prediction Model Selection in Primary Prevention: An Observational Study of Statin Eligibility Agreement Across Nine Scores in a Lithuanian Primary-Prevention Cohort. Medicina, 62(5), 979. https://doi.org/10.3390/medicina62050979

Vancouver

Navickas P, Glaveckaitė S, Lukavičiūtė-Navickienė L, Šatrauskienė A, Baranauskas A, Rinkūnienė E, et al. The Role of Cardiovascular Risk Prediction Model Selection in Primary Prevention: An Observational Study of Statin Eligibility Agreement Across Nine Scores in a Lithuanian Primary-Prevention Cohort. Medicina. 2026;62(5):979. doi:10.3390/medicina62050979

BibTeX
@article{Navickas2026,
  author = {Navickas, Petras and Glaveckaitė, Sigita and Lukavičiūtė-Navickienė, Laura and Šatrauskienė, Agnė and Baranauskas, Arvydas and Rinkūnienė, Egidija and Meškėnė, Emilija and Šileikienė, Vaida and Lycholip, Edita and Laucevičius, Aleksandras},
  title = {The Role of Cardiovascular Risk Prediction Model Selection in Primary Prevention: An Observational Study of Statin Eligibility Agreement Across Nine Scores in a Lithuanian Primary-Prevention Cohort},
  journal = {Medicina},
  year = {2026},
  volume = {62},
  number = {5},
  pages = {979},
  doi = {10.3390/medicina62050979}
}
Kostenlos starten →